ArticleCancer immunology, immunotherapy : CII2021

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.

Zhaozhen Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.